Cefdinir Pediatric Dose — Antimicrobial Reference
Cefdinir is a third-generation oral cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It is commonly used in pediatric practice for the treatment of community-acquired respiratory tract infections, otitis media, sinusitis, and mild skin and soft tissue infections caused by susceptible organisms. Its broad activity against gram-positive and select gram-negative pathogens makes it a practical outpatient antimicrobial option.
Pediatric Dosing
| Age Group | Dose | Route | Frequency |
|---|---|---|---|
| Children >6 months | 14 mg/kg/day | PO | Once daily or divided BID |
| >12 years to adults | 600 mg/day | PO | Once daily |
For a 20 kg child: 20 × 14 mg/kg/day = 280 mg/day, administered once daily or as 140 mg BID. Consult institutional protocol for maximum single-dose and daily-dose caps, as the source description does not specify an absolute maximum for pediatric patients.
Indications and Clinical Context
Cefdinir is indicated in pediatric patients older than 6 months for outpatient management of susceptible bacterial infections including acute otitis media, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and soft tissue infections. Its once-daily or twice-daily oral dosing schedule supports adherence in the outpatient setting.
As a third-generation cephalosporin, cefdinir offers enhanced gram-negative coverage compared to first- and second-generation agents while retaining activity against common gram-positive organisms such as Streptococcus pneumoniae and Staphylococcus aureus (methicillin-susceptible strains). It is not appropriate for infections caused by methicillin-resistant organisms or when parenteral therapy is clinically indicated.
Administration and Monitoring
Cefdinir is administered orally and is available as a suspension (125 mg/5 mL or 250 mg/5 mL) for younger children and capsules for older patients. It may be taken with or without food; however, concurrent administration with iron-containing products or antacids containing magnesium or aluminum should be avoided or separated by at least 2 hours, as these can significantly reduce absorption. Patients and caregivers should be counseled that cefdinir may cause red-colored stools, which is a benign interaction with iron-fortified foods or supplements.
- Monitor for hypersensitivity reactions, including cross-reactivity in patients with penicillin allergy (low but non-zero risk).
- Assess renal function in patients with known renal impairment; dose adjustment may be required (consult institutional protocol).
- Diarrhea and gastrointestinal upset are the most common adverse effects; evaluate for Clostridioides difficile-associated diarrhea if symptoms are severe or prolonged.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.